Vertex, Inc. (NASDAQ: VERX) announced that it will release its financial results for the third quarter of 2025 before the market opens on Monday, November ...
Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $438 from $439 and keeps an Equal Weight rating on the shares.
Abstract: The quadratic Lyapunov function-based method for consensus analysis of discrete-time single-integrator multiagent systems (MASs) in general time-varying directed networks is not well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback